Xencor

Bassil Dahiyat is the CEO of Xencor. To contact Bassil Dahiyat email at [email protected].

The decision makers in Xencor are Bart Burington, David Szymkowski, Debra Jeske Zack, etc. Click to Find Xencor decision makers emails.

Xencor specializes in the development of antibody and protein biotherapeutics, particularly focusing on innovative treatments for autoimmune diseases, asthma, and various types of cancer. Our proprietary protein engineering technologies enable us to create more effective and targeted therapies, including bispecific antibodies and engineered cytokines.

Xencor's protein engineering technology enhances biotherapeutics by optimizing their structure and function. This includes improving stability, reducing immunogenicity, and increasing efficacy. Our approach allows for the design of proteins that can better engage with their targets, leading to improved therapeutic outcomes for patients with challenging diseases.

Xencor primarily serves the biotechnology and pharmaceutical industries. Our focus is on developing advanced therapeutic solutions for oncology and autoimmune diseases, making significant contributions to drug development processes. We collaborate with other biopharmaceutical companies to bring innovative treatments to market.

While Xencor has a strong focus on oncology and autoimmune diseases, our protein engineering technologies are versatile and can potentially be applied to a wide range of diseases. By leveraging our expertise in antibody design and protein optimization, we aim to explore new therapeutic areas and expand our impact in the biotherapeutics landscape.

Bispecific antibodies are a key area of research at Xencor because they can simultaneously bind to two different targets, offering a novel approach to treatment. This dual targeting can enhance therapeutic efficacy and reduce side effects by precisely directing the immune response. Our bispecific antibody platform is designed to address complex diseases, particularly in oncology, where targeting multiple pathways can be crucial for effective treatment.

Xencor engages in strategic collaborations with other biotechnology and pharmaceutical companies to leverage our protein engineering capabilities in drug development. These partnerships allow us to combine our innovative technologies with the expertise and resources of our collaborators, accelerating the development of new therapies and bringing them to patients more efficiently.